Uncategorized

The longer wear time should improve Dexcom’s margins and help it compete with Abbott, RBC Capital Markets analyst Shagun Singh said.

Microbot reported positive data on its single-use endovascular robot. Elsewhere, GE Healthcare named a new business leader, and Puzzle Medical Devices raised $31 million.  

Biotech companies are already seeing regulatory delays and plenty of uncertainty after around 3,500 FDA employees were cut by the Trump administration.

The restructuring plan comes about six weeks after Teleflex announced it would split into two separate, public entities.

The number of employees laid off dropped year over year during the first quarter. BioSpace recaps the five largest layoffs, which included BMS and Novartis cuts.

Pharma stocks went on a wild ride Wednesday amid whiplashing tariff threats from the U.S. president.

The Connecticut Office of Health Strategy was the final agency to review the deal, which was first announced in February 2024.

The U.S. will now charge a 125% duty on imports from China, while most other countries will be subject to a 10% rate for 90 days.

In this episode presented by DIA, BioSpace’s head of insights Lori Ellis discusses the underrepresentation of women in clinical trials with Martin Hodosi, partner at Kearney and Melissa Laitner, director of strategic initiatives at the National Academy of Medicine.

According to Tempest, its options include a partnership or licensing deal, as well as a merger or an acquisition.